Factor Model (net +1.6)
Factor Model
net +1.6 3.5 / 10Goldman Raises Target But Keeps Sell on Approval Risk
Watch: FDA feedback on sonelokimab's regulatory pathway and timeline. A guidance meeting or positive breakthrough designation could rewire Goldman's Sell thesis; silence or negative feedback would validate the skepticism baked into current risk-reward.
Goldman Sachs nudged its price target to $11 from $10 on February 26 while maintaining a Sell rating — a classic case of a researcher backing data without backing the stock. MoonLake's lead immunotherapy candidate sonelokimab hit 81% ASAS40 response in Phase 2 (26 patients at Week 12), strong clinical numbers in axial spondyloarthritis. But Goldman remains skeptical on regulatory approval odds despite the positive readout. The company has cash runaway through H2 2027 under a Hercules Capital facility.
Clinical efficacy ≠ approval certainty. The market's already pricing in a significant approval discount — Goldman's target adjustment suggests the stock trades below intrinsic value IF sonelokimab clears the FDA, but the analyst isn't betting on that outcome. This is a high-risk clinical-stage bet where optionality matters more than current valuation.
Evidence
Fundamentals & Data ▾
Recent transactions
Get alerted when MLTX changes direction
We'll email you when our AI detects a shift — reversals, insider clusters, filing red flags.